This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Tesla, Broadcom, Comcast, Sanofi and Infosys
by Zacks Equity Research
Tesla, Broadcom, Comcast, Sanofi and Infosys have been highlighted in this Analyst Blog.
Top Research Reports for Tesla, Broadcom & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Comcast Corporation (CMCSA).
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.
Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD
by Zacks Equity Research
Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
by Kinjel Shah
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
by Zacks Equity Research
The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
by Zacks Equity Research
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
by Zacks Equity Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa
by Zacks Equity Research
Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.
Top Research Reports for Pfizer, Coca-Cola & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
by Zacks Equity Research
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale
by Kinjel Shah
Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.
Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints
by Zacks Equity Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
by Zacks Equity Research
BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals
by Kinjel Shah
Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
Should Value Investors Consider Sanofi (SNY) Stock Now?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Pharma Stock Roundup: EU Approval to PFE, AZN Products, FDA Nod to LLY New COVID Drug
by Kinjel Shah
FDA grants EUA to Eli Lilly's (LLY) new COVID antibody-drug, bebtelovimab. AstraZeneca's (AZN) Saphnelo and Pfizer's (PFE) Ngenla (somatrogon) and Apexxnar vaccine get approval in Europe
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals
by Zacks Equity Research
Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.